Atherosclerosis is defined as the build-up of plaque in the arteries, causing the narrowing of arteries and leading to the majority of heart attacks and strokes. Statin monotherapy has long been established as the gold-standard treatment, however the treatment landscape has grown over recent years with the introduction of new lipid-lowering therapies including fibrates, ezetimibe and PCSK-9 inhibitors. Further research and large-scale clinical trials are required to better compare their efficacy and safety with standard statin therapy.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
touchCARDIO Future Leaders 2026 Following the successful introduction last year of our touchCARDIO Future Leaders, we are delighted to announce that nominations are now open for the 2026 edition. This initiative celebrates the next generation of pioneers in cardiology, those whose passion, ...
Europe loses 1.7 million lives each year to cardiovascular disease, a burden that costs billions and affects millions more. The Safe Hearts Plan sets out an ambitious shift toward prevention, earlier detection and recognition of lifelong genetic risk. As expectations rise, debate is already growing over whether the strategy can translate bold goals into measurable improvements in care and outcomes across the EU.
This video highlights the efficacy and safety of lomitapide in paediatric patients with homozygous familial hypercholesterolaemia (HoFH) in the Phase III APH-19 trial.
A first-of-its-kind CAR Treg therapy has shown plaque-reducing effects in a preclinical model of atherosclerosis, signalling a potential shift toward targeted immunomodulation in cardiovascular disease. Could OxLDL-directed Tregs become the next major advance in cardio-immunotherapy?
The ESC Congress 2025 congress was an important meeting for clinical practice guidance in cardiology, with several major societies releasing long-awaited updates. As always, clinical practice guidelines remain central to cardiology, ensuring that the latest trial data and real-world evidence are rapidly translated into consistent, evidence-based patient care. This year’s congress saw the unveiling of important new documents across prevention, acute care and long-term management, equipping cardiologists with refined decision pathways, updated risk-stratification tools and clearer benchmarks to optimise patient outcomes.
S3E1_What impact does sleep have on physicians and their patients? We all know sleep is important, but what happens when physicians don’t get enough? In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from ...
In this Q&A, Dr Kheirkhah shares how her winding academic journey led her to a passion for atherosclerosis, the impact of collaborative mentorship, and her excitement for how big data, multi-omics and machine learning are reshaping cardiovascular risk prediction and disease prevention.
This August, Boston will host one of the most influential gatherings in cardiovascular medicine as the American Society for Preventive Cardiology (ASPC) convenes its 2025 Congress on Cardiovascular Disease Prevention. Set for 1–3 August 2025 at the Omni Boston Hotel at the Seaport, Boston, MA, USA, the meeting will bring together global experts, showcase cutting-edge research, and feature more than 200 abstract posters.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
Early-career cardiologists and researchers face a complex landscape: they must navigate the increasing clinical complexity of cardiovascular disease, stay abreast of rapid scientific developments and manage the pressures of clinical, academic and personal responsibilities. Recognising the need for greater support, ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
In this engaging short animation, learn how cholesterol-lowering MTP inhibitors act to reduce cholesterol in people with homozygous familial hypercholesterolemia, and explore clinical data supporting their long-term hepatic safety.
touchCARDIO is delighted to announce that Heart International has received an impressive new Impact Factor of 1.9 in the 2024 Journal Citation Reports (JCR). This achievement marks a notable increase from last year’s Impact Factor of 0.2 and highlights the journal’s growing influence in the cardiology field.
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1Â Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.